Literature DB >> 12151835

Mild cognitive impairment.

Howard Chertkow1.   

Abstract

Mild cognitive impairment is an emerging term that encompasses the clinical state between elderly normal cognition and dementia. Controversy surrounds its characterization, implementation, and definition. Mild cognitive impairment is now the focus of natural history studies, biomarker studies, along with Alzheimer's disease prevention studies. The mild cognitive impairment stage may be the optimum stage at which to intervene with preventive therapies. Depending on the cohort source and definition, between 19 and 50% of mild cognitive impairment individuals progress to dementia (usually Alzheimer's disease) over 3 years. Despite controversy, progress has been achieved in defining risk factors for progression from mild cognitive impairment to dementia. New treatments to prevent development of Alzheimer's disease are targeting mild cognitive impairment as a treatment group and neurologists will increasingly be called upon to make this diagnosis.

Entities:  

Mesh:

Year:  2002        PMID: 12151835     DOI: 10.1097/00019052-200208000-00001

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  26 in total

1.  Impact of Quantified Smoking Status on Cognition in Young Adults.

Authors:  Hemamalini Ramasamy Vajravelu; Thilip Kumar Gnanadurai; Prabhavathi Krishnan; Saravanan Ayyavoo
Journal:  J Clin Diagn Res       Date:  2015-12-01

2.  Using event-related potential P300 as an electrophysiological marker for differential diagnosis and to predict the progression of mild cognitive impairment: a meta-analysis.

Authors:  Shixiang Jiang; Changda Qu; Fengjun Wang; Yupeng Liu; Zhengxue Qiao; Xiaohui Qiu; Xiuxian Yang; Yanjie Yang
Journal:  Neurol Sci       Date:  2015-02-08       Impact factor: 3.307

3.  Mental ability performance among adults with type 2 diabetes in primary care.

Authors:  David L Mount; Michael C Lambert
Journal:  Ment Health Fam Med       Date:  2009-06

4.  Self-administered screening for mild cognitive impairment: initial validation of a computerized test battery.

Authors:  Jane B Tornatore; Emory Hill; Jo Anne Laboff; Mary E McGann
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2005       Impact factor: 2.198

5.  Body mass index over the adult life course and cognition in late midlife: the Whitehall II Cohort Study.

Authors:  Séverine Sabia; Mika Kivimaki; Martin J Shipley; Michael G Marmot; Archana Singh-Manoux
Journal:  Am J Clin Nutr       Date:  2008-12-10       Impact factor: 7.045

6.  The association between heart rate variability and cognitive impairment in middle-aged men and women. The Whitehall II cohort study.

Authors:  Annie Britton; Archana Singh-Manoux; Katerina Hnatkova; Marek Malik; Michael G Marmot; Martin Shipley
Journal:  Neuroepidemiology       Date:  2008-07-31       Impact factor: 3.282

7.  Extending the administration time of the letter fluency test increases sensitivity to cognitive status in aging.

Authors:  Roee Holtzer; Yelena Goldin; Peter J Donovick
Journal:  Exp Aging Res       Date:  2009 Jul-Sep       Impact factor: 1.645

8.  Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease.

Authors:  Michel Grothe; Laszlo Zaborszky; Mercedes Atienza; Eulogio Gil-Neciga; Rafael Rodriguez-Romero; Stefan J Teipel; Katrin Amunts; Aida Suarez-Gonzalez; Jose L Cantero
Journal:  Cereb Cortex       Date:  2009-11-04       Impact factor: 5.357

9.  Health behaviors from early to late midlife as predictors of cognitive function: The Whitehall II study.

Authors:  Séverine Sabia; Hermann Nabi; Mika Kivimaki; Martin J Shipley; Michael G Marmot; Archana Singh-Manoux
Journal:  Am J Epidemiol       Date:  2009-07-02       Impact factor: 4.897

10.  Dual-tasking and gait in people with mild cognitive impairment. The effect of working memory.

Authors:  Manuel Montero-Odasso; Howard Bergman; Natalie A Phillips; Chek H Wong; Nadia Sourial; Howard Chertkow
Journal:  BMC Geriatr       Date:  2009-09-01       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.